VBWG

65 related results for Core Curriculum


Turning White Fat to Brown: Foe to Friend or Not?

Jorge Plutzky MD, Brigham and Women's Hospital

Core Curriculum

Progress and Promise in RAAS Blockade

View/Download individual slides (82 Slides)

Core Curriculum

Vascular Dysfunction: Sequelae of Acute Hypertension

View/Download individual slides (84 Slides)

Managing CV Risk in Diabetes: Setting More Aggressive Goals to Meet a Growing Crisis

The evolving diabetes epidemic is raising concern over the adverse long-term effect on cardiovascular (CV) disease.

Core Curriculum

Myocardial Ischemia Redefined: Optimal Care in CAD

View/Download individual slides (90 Slides)

Core Curriculum

Contemporary Management of Cardiometabolic Risk

View/Download individual slides (105 Slides)

Core Curriculum

Advancing Our Understanding of RAAS Modulation in High-Risk Patients

View/Download individual slides (67 Slides)

Core Curriculum

Targeting Insulin Resistance for Vascular Protection

View/Download individual slides (120 Slides)

Core Curriculum

Contemporary Management of Myocardial Ischemia

View/Download individual slides (119 Slides)

ASCOT: New Insights on Aggressive Risk Factor Intervention to Prevent Major CV Events In Hypertensive Patients

Cardiovascular (CV) disease remains the leading cause of death in the United States, claiming more lives each year than the next four leading causes of death combined.

Core Curriculum

Antiplatelet Interventions in ACS

View/Download individual slides (104 Slides)

Core Curriculum

New Frontiers in CVD Risk Management: Optimizing Outcomes in Patients with Multiple Cardiovascular Risks

View/Download individual slides (129 Slides)

PROactive: The first prospective clinical outcomes trial of PPAR g agonists

Compared with the general population, persons with diabetes have a twofold greater absolute risk of cardiovascular (CV) disease.

Core Curriculum

Insulin Resistance and Cardiovascular Disease: New Perspectives From Vascular Biology

View/Download individual slides (94 Slides)

HOPE-TOO: Extended use of ACEI reduces CV risk and new diabetes, independent of baseline risk

Results from large clinical trials provide evidence that angiotensin-converting enzyme inhibitors (ACEIs) are effective in the treatment of cardiovascular (CV) disease.

Core Curriculum

The Renin-Angiotensin-Aldosterone System: Linking New Data and Mechanisms for Cardiovascular Risk Reduction

View/Download individual slides (93 Slides)

Core Curriculum

RAAS Modulation: Novel Strategies for Reducing Cardiovascular Risk

View/Download individual slides (82 Slides)

Core Curriculum

Improving Outcomes in Heart Failure: New Insights From Vascular Biology

View/Download individual slides (53 Slides)

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section IV - Update: RAAS manipulation and cardiovascular risk--Hope for Peace?

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

The INTERHEART Study: New data on global risk

Cardiovascular disease (CVD) is estimated to be the leading cause of mortality and morbidity worldwide.

The new mandate for multiple risk reduction

Reducing the morbidity and mortality associated with cardiovascular (CV) disease is becoming as much a public health challenge as it is a research challenge.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section V: Multiple risk and CV disease prevention

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Role of lipid lowering for prevention of cardiovascular events in type 2 diabetes

Cardiovascular (CV) disease is the primary complication and cause of death in people with type 2 diabetes mellitus, 1 accounting for nearly two thirds of deaths.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section IV: RAAS manipulation and cardiovascular risk

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section III: Heart failure: The new vascular biology imperative to blunt progression

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section II: Blunting the atherosclerotic process: The case for aggressive lipid management

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section I: Atrial fibrillation, anticoagulation, and stroke prevention

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Blunting the atherosclerotic process in patients with coronary artery disease

Statin therapy lowers serum levels of atherogenic lipoproteins and reduces cardiovascular (CV) morbidity and mortality in a wide range of patients in clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section V: Atrial fibrillation, anticoagulation, and stroke prevention

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

ASCOT-LLA: Extending benefits of statins to hypertensive patients

Hypertension and hypercholesterolemia frequently coexist and the interaction of these important risk factors increases cardiovascular risk considerably.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section IV: Antithrombotic interventions in acute coronary syndromes

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section III: Neurohormonal strategies in the failing heart

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section II: Lipid management

The VBWG Core Curriculum 2003 slide lecture compendium, Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section I: RAAS manipulation

The VBWG Core Curriculum 2003 slide lecture compendium, Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Cardiovascular considerations in treating erectile dysfunction

Impact of vascular biology in treatment of cardiovascular disease

This slide presentation covers basic science and clinical advances in treatment of erectile dysfunction, with emphasis on the cardiovascular patient.

Decrease in PAI-1 antigen is greater with ACE inhibition

Plasminogen activator inhibitor-1 (PAI-1) is a known risk factor for cardiovascular (CV) disease and myocardial infarction (MI).

HOPE: Effect of long-term therapy with ACE inhibition in high-risk women

Cardiovascular (CV) disease is currently the leading cause of death and the main hospital diagnosis in postmenopausal women.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section IV: Antithrombotic interventions in acute coronary syndromes

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section III: Neurohormonal strategies in heart failure

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section II: Lipid management

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section I: RAS manipulation

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.

Curriculum Update # 7

Managing renal disease for risk reduction: The expanding role of ACE inhibition

Chronic renal disease is a problem of increasing magnitude in the United States.

Curriculum Update # 6

Managing lipids for risk reduction: Focus on the new National Cholesterol Education Program guidelines

This Curriculum Update presents new perspectives on cholesterol management as suggested by the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III or ATP III).

Vascular Biology in Clinical Practice © Vol. 3, No. 1

Cardiovascular risk reduction in the diabetic patient

This monograph, Cardiovascular risk reduction in the diabetic patient , is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

Core Curriculum

Vascular biology for clinical practice: From basic concepts to mainstream medicine

Physicians who participated at recent Vascular Biology Working Group meetings have provided the direction for the development of these materials.

Curriculum Update #5

Interactions of lipids and RAS: Mechanisms for risk reduction

Hypertension and hypercholesterolemia, the major risk factors for atherosclerotic disease, are frequently associated.

Vascular Biology in Clinical Practice © Vol. 2, No. 3

Diabetes and cardiovascular disease: The emerging role of the endothelium and implications for treatment

This monograph Diabetes and cardiovascular disease: The emerging role of the endothelium and implications for treatment.

Lipids and RAS: Interactions that increase cardiovascular risk

Hypertension and hypercholesterolemia frequently coexist, and over the past decade, provocative data have emerged suggesting the existence of neurohormonal interactions between lipoproteins and the renin-angiotensin system (RAS).

Curriculum Update #4

Bradykinin and angiotensin-(1-7): Emerging allies in vascular function

The role of endothelial function in cardiovascular health provides an important conceptual framework for development of risk reduction strategies.

Core Curriculum

The endothelium: New insights into the origins and treatment of CAD

Participants at recent Vascular Biology Working Group meetings have reviewed and provided significant direction in the development of this slide/lecture program entitled The endothelium: New insights into the origins and treatment of CAD.

Postintervention Continuum of Care Update: Ultrasound Assessment of Plaque Dynamics

Lipids and plaque on ultrasound: New views and new dimensions

This slide lecture material is an update to the core curriculum entitled Postintervention Continuum of Care: Focus on Lipids

Curriculum Update #3

Clinical Trials Update: Tissue ACE inhibition offers new hope for treating cardiovascular disease

This Curriculum Update highlights important recent trials of tissue ACE inhibition in patients with cardiovascular disease and preserved left ventricular function.

Vascular Biology in Clinical Practice © Vol. 1, No. 4

Clinical trials update: Tissue ACE inhibition offers new hope for treating cardiovascular disease

Advances in vascular biology bring physicians the opportunity to apply new concepts in the treatment of patients with cardiovascular disease.

Data and Commentary:The HOPE Study

Effects of angiotensin-converting enzyme inhibition on cardiovascular events in high-risk patients

The Heart Outcomes Prevention Evaluation Study Investigators.

Curriculum Update #2

From hypertension to LVH and heart failure

This new program focuses on an area in which our understanding of vascular biology may have had the most profound impact on clinical practice to date.

HOPE: New validation for the importance of tissue ACE inhibition

The results of the recently published HOPE (Heart Outcomes Prevention Evaluation) study provide powerful confirmation of the clinical benefits of tissue angiotensin-converting enzyme (ACE) inhibition, now strikingly demonstrated in patients at high risk for cardiovascular events.

Vascular Biology in Clinical Practice

The vascular endothelium and CAD: New target considerations in treating the cardiovascular dysmetabolic syndrome

This discourse is based on the proceedings of a national faculty meeting of the Vascular Biology Working Group held in Orlando earlier this year that explored the clustering of metabolic abnormalities associated with what previously has been recognized by many as "syndrome X.

The vascular endothelium and CAD: New target considerations in treating the cardiovascular dysmetabolic syndrome

The attached slide materials represent the seventh in a series of slide/lecture programs that focus on what continues to be one of the most exciting new fields of emerging data: The endothelium and its role in cardiovascular health and disease.

Curriculum Update #1

Overview of clinical trials to improve endothelial function

The contents of the curriculum update represent a concise overview of clinical trials in the emerging field of study relating to the endothelium and its role in cardiovascular health and disease.

Vascular Biology in Clinical Practice © Vol. 1, No. 2

Overview of clinical trials to improve endothelial function

Fundamental views on the progression of cardiovascular disease are evolving toward a clearer understanding that the endothelium plays a central role in health and disease.

New data on the anti-ischemic effects of ACE inhibition

During the past decade, results from a number of clinical trials have revolutionized the way clinicians treat CHD and CAD.

Vascular Biology in Clinical Practice © Vol. 1, No. 1

The endothelium: Redefining the origins of cardiovascular disease

This CME monograph is the first in a series of educational programs aimed at taking the mystery out of vascular biology and making it relevant to patient care.

Core Curriculum

Endothelial function: Changing the pattern of treating CV disease

The attached slide materials represent the fifth in a series of slide/lecture programs that focus on what continues to be one of the most exciting new fields of emerging data: The endothelium and its role in cardiovascular health and disease.

Focus: Lipids and the Endothelium

The Endothelium: Impact on CAD treatment strategies

These slide materials represent the third in a series of slide/lecture programs that focus on what continues to be one of the most exciting new fields of emerging data: The endothelium and its role in cardiovascular health and disease.